 |
- Market leadership in drug-eluting stent sales outside the United
States, with international sales of nearly $200 million in 2003;
- Broad acceptance of the TAXUS system among clinicians around
the world, many of whom have praised its ease of deliverability;
- An outstanding effort by our international sales force, which
is being echoed in the U.S. Our U.S. sales team received 24 months
of pre-launch sales training, giving them expertise that is proving
crucial in introducing the TAXUS system to U.S. clinicians.
|
|
 |
|
